<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="695">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384423</url>
  </required_header>
  <id_info>
    <org_study_id>PRX-CP-018</org_study_id>
    <nct_id>NCT00384423</nct_id>
  </id_info>
  <brief_title>Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics&#xD;
      of PRX-03140 administered orally once daily for 14 days in subjects with mild Alzheimer's&#xD;
      Disease who are using a stable, well-tolerated 10 mg dose of Aricept (donepezil) but continue&#xD;
      to experience worsening AD symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of PRX-03140 during 2 weeks of treatment.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroencephalogram (EEG) changes through 14 days of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in cognition after 2 weeks of treatment.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of PRX-03140 and Aricept during 14 days of treatment.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-03140</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 60 years old.&#xD;
&#xD;
          -  On a stable 10 mg dose of Aricept for at least 90 days and able to take it in the&#xD;
             morning.&#xD;
&#xD;
          -  Diagnosis of probable Alzheimer's Disease.&#xD;
&#xD;
          -  Mild dementia.&#xD;
&#xD;
          -  You or your authorized representative provide voluntary written informed consent.&#xD;
&#xD;
          -  Not pregnant, planning a pregnancy, or capable of becoming pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other medical condition which, in the opinion of the Investigator, would&#xD;
             jeopardize your safety, impact the validity of the study results, or interfere with&#xD;
             your ability to complete the study according to the protocol.&#xD;
&#xD;
          -  Intolerance to Aricept.&#xD;
&#xD;
          -  Dementia other than Alzheimer's type.&#xD;
&#xD;
          -  Parkinson's Disease.&#xD;
&#xD;
          -  History of seizure or epilepsy.&#xD;
&#xD;
          -  History of stroke.&#xD;
&#xD;
          -  Participation in another research study within last 30 days.&#xD;
&#xD;
          -  Enrollment in any previous research study testing PRX-03140.&#xD;
&#xD;
          -  Use of prescription cognitive enhancing medications (except Aricept) or MAO inhibitors&#xD;
             within last 4 weeks.&#xD;
&#xD;
          -  Use of tobacco products within last 4 weeks.&#xD;
&#xD;
          -  Positive blood screen for Hepatitis B surface antigen or Hepatitis C antibody.&#xD;
&#xD;
          -  Positive urine screen for alcohol or drugs of abuse or history of drug or alcohol&#xD;
             abuse within last 6 months.&#xD;
&#xD;
          -  Major surgery within last 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group, Inc</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest CLinical Research</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center for Clinical Studies</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Home and Hospital for the Aged</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berma Research</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience, Inc</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Gary Booker, MD</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research of the Berkshires</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Johns Office Building</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, LLC</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Neuro Research, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>October 4, 2006</study_first_submitted>
  <study_first_submitted_qc>October 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>January 29, 2008</last_update_submitted>
  <last_update_submitted_qc>January 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2008</last_update_posted>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>AD</keyword>
  <keyword>PRX-03140</keyword>
  <keyword>Dementia</keyword>
  <keyword>Epix</keyword>
  <keyword>Predix</keyword>
  <keyword>Cognition enhancing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

